New Directions for Imaging
Imaging can provide data on the results of cancer gene therapy, such as if new agents
are hitting their target (targeted therapy), cell movement through the body and
cellular apoptosis. All of these capabilities will need to be tested using clinical trials.
The American College of Radiology Imaging Network (ACRIN)
ACRIN is a cooperative group formed to conduct cancer-imaging research. As quoted
from there website: "We have experienced groundbreaking developments within the
last decade. We are grateful to have been instrumental in facilitating clinical research
that is making a difference in the lives of cancer patients.
Looking to future research plans, ACRIN anticipates developing even more precise
quantitative approaches to diagnosis and image-guided therapy. Specific objectives
- Surveillance of high-risk populations
- Administration of targeted therapies
- Use of biomarkers to evaluate therapeutic response".
The new Experimental Imaging Sciences Committee is charged with exploring new
modalities, new uses for established modalities, and new equipment.
Surgical Clinical Trials
The American College of Surgeons Oncology Group (ACOSOG) was established
primarily to evaluate the surgical management of patients with malignant solid
tumors through conducting clinical trials to document best practices.
ACOSOG includes general and specialty
surgeons, representatives of related oncologic
disciplines and allied health professionals in
academic medical centers and community
practices throughout the United States of
America and other countries.
The mission and infrastructure of the American College of Surgeons Oncology Group
(ACOSOG) creates unique opportunities to collect human biospecimens from early
stage cancer for clinical correlative science studies.
The Group's focus on surgical trials allows for the prospective collection of fresh
tissue specimens from operative procedures. Neoadjuvant trials conducted by the
Group facilitate the collection of biospecimens from treatment-na´ve patients and
additional, serially timed specimens during the peri-operative and post-operative
(adjuvant) phase of treatment.
The Group's geographically broad-based surgeon membership provides an
infrastructure of clinical trialists, who are able to collect biospecimens from patients
treated in a large number of primary, academic and non-academic medical centers
that are often not represented in other cooperative group studies.
The ACOSOG Central Specimen Bank (CSB) was created to capitalize upon these
unique features of ACOSOG in order to create a quality-controlled biospecimen
repository with emphasis on frozen tissue specimens from early stage cancer that are
particularly well suited for molecular correlative science studies.
Radiology Clinical Trials
The Radiation Therapy Oncology Group« (RTOG«) systematically tests novel
radiotherapy approaches against cancer and also pursues fully integrated
translational and quality of life research to support and further this effort.
RTOG is also a leader in formally evaluating the integration of optimized radiotherapy
with new classes of anti-cancer therapies and has completed and conducted a
number of practice- and paradigm-changing trials.
RTOG maintains a roster of 40 active studies devoted to the group's primary disease
sites: central nervous system, head & neck, lung, gastrointestinal (esophagus,
stomach, pancreas, anal canal, and rectum), genitourinary (bladder and prostate),
breast, and cervix.
- Improve the survival outcome and quality of life of
adults with cancer through the conduct of highquality
- Evaluate new forms of radiotherapy delivery,
including stereotactic radiotherapy, brachytherapy,
3-dimensional conformal radiotherapy (3-DCRT), and
intensity-modulated radiotherapy (IMRT) in the context of clinical research.
- Test new systemic therapies in conjunction with radiotherapy, including
chemotherapeutic drugs, hormonal strategies, biologic agents, and new classes
of cytostatic, cytotoxic, and targeted therapies.
- Employ translational research strategies to identify patient subgroups at risk for
failure with existing treatments and identify new approaches for these patients.